B. Riley initiated coverage of Actuate Therapeutics (ACTU) with a Buy rating and $20 price target The firm views the company’s lead asset elraglusib as a “transformative” advancement in pancreatic ductal adenocarcinoma treatment. In a Phase 2 study, elraglusib delivered an “unprecedented” survival benefit in the front-line setting with a 37% reduction in death risk that remained consistent in more aggressive disease characterized by the presence of liver metastasis, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACTU:
- Actuate Therapeutics, Inc.: Strategic Regulatory Advances and Promising Clinical Data Drive Buy Rating
- Actuate, Incyte, University of Pittsburgh collaborate on elraglusib trial
- Actuate Therapeutics files to sell 1.33M shares of common stock for holders
- Promising Clinical Developments and Valuation Support Buy Rating for Actuate Therapeutics
- Actuate Therapeutics announces end of Phase 1 portion of elraglusib study